Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.

NEW YORK – ProteinQure said on Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.